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Extreme presentations of common disease in children are often presumed to be of Mendelian 
etiology, but their polygenic basis has not been fully explored. We tested whether children with 
significant fracture history and no osteogenesis imperfecta (OI) are at increased polygenic risk 
for fracture. A childhood significant fracture history was defined as the presence of low-trauma 
vertebral fractures or multiple long bone fractures. We generated a polygenic score of heel 
ultrasound derived speed of sound, termed “gSOS”, which predicts risk of osteoporotic fracture. 
We tested if individuals from three cohorts with significant childhood fracture history had lower 
gSOS. A Canadian cohort included 94 children with suspected Mendelian osteoporosis, of which 
68 had negative OI gene panel. Two Finnish cohorts included 59 children with significant 
fracture history and 22 with suspected Mendelian osteoporosis, among which 18 had no OI. 
After excluding individuals with OI and ancestral outliers, we generated gSOS estimates and 
compared their mean to that of a UK Biobank subset, representing the general population. The 
average gSOS across all three cohorts (n=131) was -0.47 SD lower than that in UK Biobank 
(n=80,027, P= 1.1 x 10-5). The gSOS of 78 individuals with suspected Mendelian osteoporosis 
was even lower (-0.76 SD, P =5.3 x10-10). Among the 131 individuals with a significant fracture 
history, we observed 8 individuals with gSOS below minus 2SD from the mean; their mean 
lumbar spine DXA-derived BMD z-score was -1.7 (SD:0.8). In summary, children with 
significant fracture history but no OI have an increased burden of common risk alleles. This 
suggests that a polygenic contribution to disease should be considered in children with extreme 






Children with phenotypes at the extremes of common disease spectrum are sometimes presumed 
to have a monogenic Mendelian disease. Typical examples include extreme presentations of 
obesity(1), short or tall stature(2), and autism spectrum disorders(3). However, in most cases, 
children with such phenotypic presentations investigated with targeted gene panels are found to be 
negative for mutations in known disease-related genes(4). While such cases could still be caused 
by Mendelian mutations in unknown genes, it is also possible that such patients have an increased 
burden of common risk alleles, which individually confer a small risk of disease, but taken together 
can have large effects on disease risk(5). The extent to which common risk alleles of small effect 
on disease risk contribute to presumed Mendelian presentations of a disease is not well known.  
 
We sought to explore the contribution of common risk alleles to a bone fragility phenotype in 
children. The rationale for choosing this phenotype as an example of extreme presentation of 
common disease in childhood is twofold. First, fractures are indeed common in childhood, 
affecting as much as half of otherwise healthy children and adolescents(6). However, it is rare for 
children to have repeated long-bone fractures or low-trauma vertebral compression fractures, and 
such cases are often considered to be due to an underlying monogenic disorder(7). The most 
common fracture-related monogenic disorder is osteogenesis imperfecta (OI), a connective tissue 
disease with typical extraskeletal findings, such as blue sclerae and dentinogenesis imperfecta(8). 
OI is a Mendelian disorder caused by mutations in more than 20 different genes, with an estimated 
prevalence of 1 in 20,000(9). These mutations are present in 97 to 99% of cases with typical 
extraskeletal findings of OI (10), but when these findings are absent, a molecular diagnosis of OI 
explains less than a third of cases of bone fragility(10).  However, if the cause of these fractures 
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were polygenic, this information could be important for treatment and identification of other 
family members at risk. The second reason for studying significant fracture history as an example 
of extreme presentation of common disease, is that bone density is a highly heritable trait, for 
which hundreds of common risk alleles have been identified through genome-wide association 
studies (11-16). An emerging method which enables identification of individuals at increased 
genetic risk for fracture and other common diseases, is through the use of polygenic risk scores, 
which use genotypes to assess risk of heritable diseases and clinically-relevant traits(17-19). We 
have recently demonstrated that 24% of the variance, as measured by r2,  in heel ultrasound-derived 
speed of sound (SOS), a skeletal measure of fracture risk, can be predicted from genotypes alone—
approximately five fold more than can be predicted from conventional clinical risk factors(17).  
 
Therefore, in the present study, we computed the genetically predicted heel SOS (gSOS) using a 
polygenic risk score in three separate cohorts of individuals with a significant fracture history in 
childhood, but no typical extra-skeletal symptoms, skeletal deformities, or family history of OI. 
Next, we compared their gSOS to that of the general population, using as a control population, a 
large sample of 80,027 individuals from UK Biobank, a population-based cohort. Finally, we 
assessed within these cohorts the number of individuals with extremely low gSOS (defined as 
below 2 standard deviations [SD] from the mean), and their average lumbar spine BMD. 
 





The population of this study comprised young individuals from three separate cohorts, with a 
significant fracture history but no typical OI phenotype (Figure 1), and a control population from 
UK Biobank.  
 
The Canadian cohort included 94 subjects under age 21 years with suspected Mendelian cause of 
their fractures and no family history of OI. Of them, 26 had a positive and 68 had a negative gene 
panel comprising 21 OI-related genes. 67 of these 68 children with a negative gene panel were 
genome-wide genotyped (described below). In this cohort significant fracture history was defined 
as the presence of one or more of the following: one or more long-bone fractures of the lower 
extremities; two or more long-bone fractures of the upper extremities; or one or more vertebral 
compression fracture.  All individuals were evaluated either at the Shriners Hospital for Children 
in Montreal or at the Children’s Hospital of Eastern Ontario in Ottawa. A detailed description of 
the cohort of 94 children who underwent OI gene panel sequencing can found in a previous 
publication(10). This study was approved by the Institutional Review Board of McGill University 
and the Research Ethics Board at the Children’s Hospital of Eastern Ontario. Consent to perform 
next generation sequencing for the present study was obtained from all the participants and their 
parents. 
 
The two additional cohorts comprised subjects from Finland with a significant fracture history, as 
defined by the International Society for Clinical Densitometry (ISCD) criteria. Specifically, 
participants had sustained at least one vertebral fracture; two long-bone fractures before age 10 
years; or three long-bone fractures before age 19 years.  
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 The first Finnish cohort consisted of 59 genome-wide genotyped “fracture-prone” children, aged 
4 to 16 years. These children had been previously treated for a radiologically confirmed fracture 
and assessed for previous fracture history at the Children's Hospital in Helsinki during a 12-month 
recruitment period. All of them met the criteria for a clinically significant fracture history 
according to the above ISCD criteria, but only 19 of them met the criteria for childhood 
osteoporosis, which requires presence of one or more vertebral compression fractures, or in 
addition to a significant long-bone fracture history a lumbar spine BMD z-score < -2.0. Also, none 
of these children had secondary osteoporosis or a clinical diagnosis of OI. Since concordance 
between clinical and molecular diagnosis of OI is high(20), sequencing for COL1A1 and COL1A2, 
the most common OI genes, was not performed, because it was unlikely that these mutations would 
explain their bone fragility. However, these children were assessed for mutations in selected OI-
related genes (LRP5, PLS3, WNT1)(21, 22) and copy-number variants (CNVs)(23), and in all cases 
pathogenic mutations were excluded.  A detailed description of this sample can be found in a 
previous publication (24).  
 
The second Finnish cohort consisted of 22 genome-wide genotyped subjects with a clinical 
diagnosis of childhood-onset primary osteoporosis and clinical suspicion of a Mendelian disorder. 
In all individuals OI was clinically excluded, 9 individuals had been assessed with COL1A1 and 
COL1A2 sequencing as part of their clinical assessment and were regarded as having early-onset 
primary osteoporosis of unknown cause. In the remaining 13 subjects whole-genome sequencing 
was performed for research purposes. In 4 of these 13 individuals a known monogenic cause was 
subsequently identified. After exclusion of these 4 subjects, 18 individuals from this cohort (9 with 
negative COL1A1 and COL1A2 sequencing and 9 with negative whole-genome sequencing) were 
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included in the present study. The studies recruiting the two Finnish cohorts were conducted in 
accordance with the Declaration of Helsinki, and both studies were approved by the Ethics Review 
Board at Helsinki University Hospital. All patients and/or their guardians gave a written informed 
consent before participation. 
 
To evaluate the polygenic risk for fracture in the three cohorts separately, and after combining 
them to a single “juvenile fracture” cohort, we generated gSOS (described below) and compared 
the resultant values to those of a large control group representative of the general population, 
specifically a sample of 80,027 White British individuals from UK Biobank. UK Biobank is a 
large-scale population-based health study which consists of 502,543 volunteer adult participants 
(mean age 57 years) from the United Kingdom(25). 426,811 UK Biobank participants have been 
genome-wide genotyped using Affymetrix arrays, and their genotypes were then imputed to the 
Haplotype Reference Consortium(26, 27). UK Biobank has ethical approval from the Northwest 
Multi-centre Research Ethics Committee, and informed consent was obtained from all participants.  
 
Genotypes do not change through the lifetime of an individual, and therefore we would not expect 
the distribution of gSOS to differ between a healthy adult population (such as UK Biobank) and a 
healthy pediatric population. Nevertheless, since there could be some response bias in UK 
Biobank, as a population of mainly elderly people, we assessed the average gSOS of a healthy 
pediatric cohort, and compared it to that of UK Biobank. To do so, we used available genotype 
data from the VIDI study, originally designed to test the effects of an interventional dose of vitamin 
D in a cohort of Finnish infants(28, 29). The VIDI study included 975 healthy new-borns, recruited 
between January 2013 to June 2014 at Kätilöopisto Helsinki Maternity Hospital, Helsinki, Finland. 
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All children included in the study had normal birth weight and were born at term from healthy 
mothers of Northern European descent (30). Thus, we can assume that this healthy Finnish infant 
population is representative of a healthy pediatric population of European ancestry. Among the 
975 VIDI participants, 928 individuals underwent genome-wide genotyping. The VIDI study was 
approved by the Research Ethics Committee of the Hospital District of Helsinki and Uusimaa. All 
guardians of the VIDI participants gave a written informed consent before participation. 
 
Genome-wide genotyping, quality control, imputation, and control for population 
stratification 
Genotyping for the Canadian cohort was conducted using the UK Biobank Axiom array at the 
McGill University and Genome Quebec Innovation Centre (MUGQIC). This array contains 
~820,000 SNPs. Quality control conducted at Affymetrix for UK Biobank revealed that a total of 
794,409 SNPs were reliable, therefore, this later count of SNPs was used for further quality control, 
which included removing individuals with genotype missingness > 5% and heterozygosity > 3 SD. 
Genotype imputation was performed using the Sanger Imputation Service. Genotype data was pre-
phased by the Sanger Imputation Service using EAGLE6, (31) following by imputation using 
PBWT 7(32) to the Haplotype Reference Consortium (r1.1)(31). The imputation process resulted 
in 39,131,578 autosomal SNPs.  Population stratification was assessed using EIGENSTRAT 
version 6.0.14. To assess for ancestry outlier removal in the principal component analysis (PCA), 
we combined the genotype data from the Canadian cohort with data from 1000 Genomes phase 3 
(N=2,504). Analysis using the PLINK 2 “--pca ” command was performed to obtain the top 10 
principal components. We used the two top principal components to define outliers. 
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Genotyping for two Finnish fracture cohorts and of the VIDI study was conducted using the 
Illumina Infinium Global Screening Array v1.0 at the Human Genomics Facility (HuGe-F) at 
Erasmus MC, Netherlands. A total of 686,085 markers across the genome where genotyped, which 
included 682,209 biallelic SNPs. The Will Rayner’s HRC prep tool and bcftools was used to fix 
strand issues and harmonize the data with the Haplotype Reference Consortium (r1.1) reference 
before imputation(31). For imputation, we used the same pipeline as the one applied to the 
Canadian cohort. The imputation resulted in a total of 40,359,612 SNPs. PCA controlling for 
population stratification was conducted using the TRACE software (LASER suite) (33, 34). For 
this analysis, a 4-dimension reference space was created using 503 individuals from the European 
subset of the 1000 genomes data phase 3, of which 99 individuals are of Finnish descent. A 20-
dimension genetic map was created by applying PCA in each individual, after merging it with the 
reference population. All individuals were then projected from their 20-dimensional map in to the 
4-dimensional reference space. To define outliers (individuals not clustering with the Finnish 
reference), a 4 standard deviation cut-off was chosen graphically.  
 
gSOS calculation 
A detailed description of the algorithm used to calculate heel ultrasound gSOS has been described 
previously.(17) Briefly, 341,449 individuals from UK Biobank with SOS measures were used to 
develop polygenic risk score models using LASSO regression. The optimal prediction model was 
determined in 5,335 separate individuals and termed “gSOS”. Its utility in fracture risk screening 
was tested in 5 validation adult cohorts totaling 10,522 participants, and its performance 
characteristics for predicting fracture risk were similar to measured SOS and femoral neck BMD. 
gSOS was calculated in individuals of European descent only, defined  by a population ancestry 
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cluster analysis as UK Biobank individuals being within the same cluster as the GBR (British in 
England and Scotland) 1000 Genomes population.(17) Computation of gSOS in the three juvenile 
fracture cohorts and in the VIDI study was performed by multiplying the allele count for each SNP 
allele included in gSOS with the respective beta estimate, derived from the LASSO regression, 
and by adding the counts across all the alleles for each individual. Thus, a single score was 
allocated to each participant. To facilitate interpretation and comparisons, gSOS measures of the 
juvenile fracture cohort and the control cohort from UK Biobank were merged and then 
standardized to a mean of 0 and a standard deviation of 1.  
 
Clinical analyses 
 In all three fracture cohorts, DXA was performed in the antero–posterior direction at the lumbar 
spine (L1–L4) using a Hologic QDR Discovery device (Hologic Inc., Waltham, MA, USA). 
Lumbar spine areal BMD results were transformed to age- and gender-specific z-scores (zBMD) 
using published reference data. A detailed description of the assessment of fractures (vertebral and 
non-vertebral) in the Canadian and the “fracture-prone” Finnish cohort can be found in previous 
publications(10, 24).  
 
Statistical Analysis 
Descriptive statistics of the Canadian and the two Finnish cohorts, appear as means and standard 
deviations or percentages. The comparisons of the means of the gSOS measurements in the three 
fracture cohorts and the combined juvenile fracture cohort with the mean gSOS of UK Biobank, 
as well as of the means of gSOS between UK Biobank and the VIDI cohort, were performed using 
a student’s t-test.  
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As a sensitivity analysis, we computed gSOS estimates omitting SNPs with low info-score (<0.4) 
and compared the newly computed mean gSOS to the mean gSOS of UK Biobank. We also 
computed the mean gSOS separately in the Canadian and the two Finnish cohorts, and compared 
them to the control population from UK Biobank. Additionally, we conducted a sensitivity analysis 
on a “suspicion of monogenic disease” cohort, which was the result of the merging of the Canadian 
to the “primary osteoporosis” Finnish cohort, since all these individuals had been referred for 
investigation with OI gene panel.  Finally, we also computed the mean gSOS of the subset of 






The clinical characteristics of the three fracture cohorts (excluding individuals who failed 
genotyping or genotype quality control, and who were outliers in the PCA) appear in Table 1. The 
characteristics of the adult control cohort from UK Biobank are provided in Supplemental Table 
1. 
 
Genotyping and assessment of population stratification 
Among the 67 individuals genotyped in the Canadian cohort, two were removed due to extreme 
heterozygosity rates. Results of the PCA are depicted in Supplemental Figure 1, and demonstrate 
5 outliers in EIGENSTRAT, which are outside the 1000 Genomes European super-population, 
whereas the inliers largely overlap or are in close proximity to the European super-population. 
These outliers were removed from further analyses. The average SNP info score for SNPs included 
in the calculation of gSOS was 0.89.  
 
All 77 genotyped samples from the two Finnish fracture cohorts (59 from the “fracture-prone” and 
18 from the “primary osteoporosis” cohort) passed quality control. Among the 928 genotyped 
individuals from the VIDI cohort, 7 samples were excluded due to increased genotype missingness 
(>5%), and 1 individual was excluded due to a discordant genotype-inferred and reported sex.  The 
average info score for SNPs used to calculate gSOS was 0.92. Results of the PCA for the two 
Finnish fracture cohorts are shown in Supplemental Figure 2. Six individuals from the “fracture-
prone” cohort were excluded since they did not cluster with the Finnish reference in the 4-




The average gSOS in the combined juvenile fracture cohort (n= 131) was -0.47 SD lower than that 
in UK Biobank (n=80,027, average gSOS: 0.00, p-value for comparison: 1.1 x 10-5) (Table 2). 
Figure 2 shows the distribution of gSOS values of the juvenile fracture cohort, projected on the 
distribution of gSOS measurements in UK Biobank. The average gSOS in the Canadian cohort 
(n= 60) was -0.82 SD and was lower than that in the control population from UK Biobank (p-value 
for difference: 3.7 x 10-9). The calculated gSOS in the “primary osteoporosis” Finnish cohort 
(n=18), was -0.54 SD lower than that of the UK Biobank general population (p-value for 
comparison: 0.04). In contrast, the 53 individuals from the “fracture-prone” Finnish cohort, had an 
average gSOS of -0.04 SD, which was comparable to the mean in UK Biobank (p-value for 
comparison: 0.77). The average gSOS of 898 individuals from the VIDI cohort was -0.01 SD, and 
it was similar to the average gSOS of UK Biobank (p-value for comparison: 0.69). When 
comparing the average gSOS of the 3 fracture cohorts and of the entire juvenile fracture cohort to 
that in the VIDI cohort, we obtained similar results with the respective comparisons with UK 
Biobank (data not shown). This provides evidence that, as expected, UK Biobank, an adult cohort, 
and the VIDI cohort, a pediatric cohort, can be used interchangeably as control populations in our 
study, representing both the general European population. 
 
Sensitivity analyses 
The “suspicion of monogenic disease” subset consisted of 78 individuals who had undergone gene 
panel sequencing or otherwise extensively examined genetically (Canadian cohort and Finnish 
“primary osteoporosis” cohort). Their average gSOS was -0.76 SD lower than in UK Biobank (p-
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value for comparison: 5.3 x10-10). The gSOS of the subset of individuals (n=57) who satisfied the 
definition of “childhood osteoporosis” from all 3 cohorts (n=27 from the Canadian, n=15 from the 
Finnish “primary osteoporosis” and n=15 from the Finnish “fracture-prone” cohort) was -0.67 SD 
lower than UK Biobank (p-value for comparison: 1.9 x10-5) (Table 2). 
 
Among the 20,796 SNPs used to compute gSOS in the Canadian cohort, 1,467 SNPs had low info 
score (<0.4), while among the 21,716 SNPs used to compute gSOS in the two Finnish cohort, 
1,071 SNPs had info score below 0.4. We undertook a sensitivity analysis by recomputing gSOS 
excluding these SNPs in all three cohorts, and compared the new mean gSOS to that of UK 
Biobank. We found that gSOS was still lower in the juvenile fracture cohort (average gSOS -0.40 
SD) compared to UK Biobank (p-value: 7.8 x10-5). The info-score filtered gSOS estimates 
separately in the three cohorts appear in Table 2. 
 
Participants with gSOS below minus 2 SD 
We next assessed the number of individuals with fractures with gSOS below 2 SD from the mean 
of the general population, since this could be an informative and clinically relevant cut-off for 
fracture risk stratification. Of the 131 individuals in the combined juvenile fracture cohort, 8 
individuals (6%) had standardized gSOS below minus 2, compared to 3 individuals (2.5%) which 
would be expected by chance alone. Among these 8 individuals, there were 5 individuals from the 
Canadian cohort, 2 individuals from the fracture-prone Finnish cohort, and 1 individual from the 
primary osteoporosis Finnish cohort. The average zBMD of these 8 individuals was -1.7 (SD: 0.8). 
Notably, the average heel ultrasound-derived SOS z-score in 1,878 adult participants from the 




In this study, we found that young individuals presenting with increased bone fragility and 
presumed to have a monogenic etiology of their condition tended to have an increased burden of 
common risk alleles. Specifically, we found that gSOS in this population was, on average, half a 
standard deviation below that of the general population. These findings imply that an important 
proportion of patients with apparent monogenic - Mendelian disease and a significant fracture 
history in childhood and suspicion of OI, could have an increased burden of common risk alleles 
predisposing them to this clinical presentation. 
 
These results may have clinical implications, since they imply that polygenic predisposition to 
disease may be present in an important proportion of individuals who are presumed to have 
Mendelian forms of disease. As our ability to quantify polygenic risk improves through rapidly 
evolving polygenic risk scores, the ability to estimate this risk may inform clinical care not only 
of fracture, but of other traits and diseases, such as extreme presentations of autism(3), obesity(1) 
and short or tall stature(2), which appear to have both monogenic and polygenic forms of the 
disease. The accuracy of polygenic risk scores(35) depend in large part on the sample size from 
which they are calculated, suggesting that further increases in sample sizes of genome-wide 
genotyped populations will help to improve their clinical performance and allow the establishment 
of clinically relevant cut-offs for risk stratification. In the absence of such cut-offs, polygenic risk 
scores, although not deterministic, can still be informative and complement other approaches, such 
as disease-specific gene panel sequencing, whole exome or genome sequencing. In settings where 
clear cut-offs are set, knowing the polygenic predisposition to disease can directly influence 
 18 
clinical management, and may also decrease its cost, since it is based upon genome-wide 
genotyping, which costs below $50 USD, and is considerably less expensive than most 
sequencing-based tests, whose cost remains over $1,000 USD (genome.gov/sequencingcosts).  
 
Our study has important limitations. Our three fracture cohorts are heterogeneous, with the 
individuals in the Finnish “fracture-prone” cohort presenting a milder phenotype compared to the 
two other cohorts. Despite this, when taken together, participants in all three cohorts had a 
definition of significant fracture history in childhood and no clinical or molecular diagnosis of OI. 
We chose a genetic predictor of SOS and not of BMD as a measure of fracture risk, since the 
available SOS GWAS(15) is larger than existing BMD GWASes, which allowed the development 
of a more performant polygenic risk score for SOS than previous existing polygenic scores for 
BMD(36). Also, SOS has a gradient of risk for osteoporotic fractures similar to BMD and a recent 
meta-analysis described its effect on fracture risk, allowing for the development of a SOS-based 
screening model(37). The predictive performance of gSOS on childhood heel ultrasound SOS has 
not been tested, yet we assumed that it can be used as a predictor of pediatric BMD, since there is 
a large overlap between findings of pediatric and adult BMD GWAS (38). Although there may be 
a variation in the effect sizes of the BMD-related SNPs according to age, with the effects being 
generally attenuated in the pediatric studies, the actual loci remain largely similar, as indicated by 
a recent life-course GWAS on total body BMD(38). Also, since there is no consensus on a 
clinically-relevant cut-off value for gSOS, below which an individual is considered at increased 
risk for fracture, we were not able to test the performance of gSOS as a screening tool in our 
juvenile fracture cohort. Replication of our findings in larger cohorts of children with a significant 
fracture history is warranted, and might allow testing the accuracy of various cut-off values of 
 19 
gSOS in identifying individuals at risk. Further, the polygenic risk score deployed here was derived 
from a European-ancestry population and was tested in individuals of European ancestry. The 
performance of such a score in other ancestral populations remains to be tested. Finally, as 
mentioned above, it would have been interesting to assess how gSOS affects risk of fracture within 
individuals with an identified Mendelian cause of bone fragility. This could be the scope of a future 
study on a larger cohort of children diagnosed with OI. 
 
In summary, we provide evidence that a portion of children with bone fragility and no extraskeletal 
signs of OI have an increased burden of common gene variants which predispose to osteoporotic 
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Figure 1. Flow diagram with the inclusion criteria to the study across the 3 pediatric 
fracture cohorts. OI: osteogenesis imperfecta; QC: genotype quality control; PCA: principal 
component analysis; COL1A1: Collagen type I alpha 1 chain; COL1A2: Collagen type I alpha 2 
chain; LRP5: Low-density lipoprotein receptor-related protein 5; PLS3: Plastin 3; WNT1:  Wnt 
Family Member 1; CNVs: copy number variants; ISCD: International Society for Clinical 
Densitometry 
Figure 2. Comparison of the distribution of gSOS in the juvenile fracture cohort vs in UK 
Biobank. 
Density plot of the distribution of gSOS in 131 individuals of the juvenile fracture cohort (in 
pink), projected on the distribution of gSOS in 80,027 subjects from UK Biobank (in blue). 











Finnish cohort “primary 
osteoporosis” 
N* 60 53 18 
Age 11.4 (1-21.2) 10.3 (4.3-16.8) - 
Females 22 (37%) 16 (30%) - 
zBMD -1.82 (1.3) -0.46 (1.0) -1.84 (1.34) 
Vertebral fracture 11 (18%) 14 (26%) 13 (72%) 
Any long bone fracture 54 (90%) 49 (92%) 16 (89%) 
Long bone fracture N 2.5 (0-12) 3.0 (0-7) 2.0 (0-7) 
OI gene panel negative not performed negative 
 
*N of individuals included in the gSOS analysis after QC and excluding outliers at PCA 
Values for zBMD are expressed as means and SD. Age and long bone fracture N are expressed 
as median and range. zBMD: lumbar bone mineral density z-score; OI: osteogenesis imperfecta; 







Table 2. Results of the main analysis and sensitivity analyses.  
Main analysis with gSOS estimates in the fracture cohorts and in the VIDI cohort and their 
comparison to UK Biobank. Sensitivity analyses with gSOS estimates in subsets of the main 
cohort, and in the main cohort excluding low-info score SNPs from gSOS, and their comparison 
to UK Biobank. Values are expressed in means and standard deviations. gSOS: genetically 
predicted speed of sound; SNP: single nucleotide polymorphism; VIDI: Vitamin D Intervention 





comparison with UK 
Biobank 
Main analysis 
UK Biobank (n=80,027) 0.00 (1.00) - 
VIDI (n=898) 0.01 (1.00) 0.69 
All juvenile fracture (n=131) -0.47 (1.00) 1.1 x10-5 
Canadian cohort (n=60) -0.82 (0.90) 3.7 x10-9 
Finnish “fracture prone” cohort (n=53) -0.04 (1.06) 0.77 
Finnish “primary osteoporosis” cohort (n=18) -0.54 (1.01) 0.04 
Sensitivity analyses 
“Suspicion of monogenic disease” subset (n=78) -0.76 (1.06) 5.3 x10-10 
“Childhood osteoporosis” subset (n=57) -0.67 (1.07) 1.9 x10-5 




























































































































Supplemental Tables and Figures 
 
Supplemental Table 1. Cohort characteristics of the UK Biobank control cohort 
 
 UK Biobank control cohort 
Sample size 80,027 
Age (mean/SD) 56.77 (8.03) 
Females (counts (%)) 43.7 (55%) 
SOS (mean/SD) -0.02 (0.99) 
Prevalent fracture (counts (%)) 8,244 (10.3%) 
 
SOS: speed of sound from heel ultrasound  
Supplemental Figure 1. Principal component analysis in the Canadian cohort. 
Plot depicts comparison of the top 2 principal components (eigen$V4 vs eigen$V3) from the 
analysis of the 65 participants (in black dots) projected on 2,504 individuals from 1000 
Genomes, that cluster in 5 ancestries, with the pink dots representing the European cluster. AFR: 
African; AMR: Ad Mixed American; EAS: East Asian; EUR: European; SAS: South Asian 
 
 




























Supplemental Figure 2. Principal component analysis of the two Finnish cohorts.  
Using the European subset of the 1000 genomes phase 3 population, including 99 Finnish 
individuals, a 4-dimensional reference ancestry map was created. The subjects in the two study 
cohorts have then been projected onto the reference map (black dots). The black boxes represent 
the space within 4SD of the 99 Finnish individuals. a. Fracture prone cohort. b. Primary 
osteoporosis cohort. PC1: principal component 1; PC2: principal component 2; PC3: principal 
component 3; GBR: British in England and Scotland; IBS: Iberian Population in Spain; CEU: 
Utah Residents (CEPH) with Northern and Western European Ancestry; TSI: Toscani in Italia; 
FIN: Finnish in Finland 
 
